Journal
CURRENT DIABETES REPORTS
Volume 16, Issue 12, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-016-0825-4
Keywords
Diabetes; Diabetic retinopathy; Diabetic macular edema; DME; Ranibizumab; Bevacizumab; Aflibercept
Categories
Funding
- Alimera
- Santen
- Regeneron
- Genentech
- Alcon
- Allergan
- Bausch and Lomb
- Novartis
- Regenxbio
- Replenish
Ask authors/readers for more resources
The prevalence of diabetes is growing at epidemic rates in the USA. Diabetic retinopathy develops in a large proportion of patients and is a leading cause of blindness worldwide. Systemic management of diabetic retinopathy has included glycemic, hypertension, and lipid control. Local ophthalmic treatment in the form of focal/grid or panretinal laser photocoagulation has been shown to prevent vision loss in diabetic edema and proliferative diabetic retinopathy, respectively. The introduction of anti-vascular endothelial growth factor for diabetic macular edema and retinopathy has provided clinicians with improved clinical outcomes with potentially less damaging effects than laser.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available